On March 13, 2026, Bluejay Diagnostics, Inc. (the "Company") issued a response letter to NorthStrive Fund II LP ("NorthStrive") following a communication received from NorthStrive on March 11, 2026. The letter addressed NorthStrive's suggestions regarding a potential acquisition of a Phase-1-ready therapeutic program targeting refractory chronic cough, which could expand Bluejay's clinical pipeline. In the response, Bluejay emphasized its current focus on advancing its Symphony™ platform and critical care biomarker menu, including the completion of the SYMON™ II clinical study and preparation for FDA regulatory submission. The Company believes that concentrating its resources on these critical initiatives is essential for unlocking long-term shareholder value. Bluejay acknowledged the acquisition opportunity presented by NorthStrive and stated that the Board and management would evaluate it as part of their strategic decision-making process. They assured stakeholders that any potential risks and opportunities associated with such a strategy would be carefully assessed to determine its impact on the value of the Company's outstanding shares. The letter also invited NorthStrive to provide additional diligence information regarding the potential acquisition, indicating a willingness to consider further discussions. This proactive communication reflects Bluejay's commitment to transparency and engagement with its investors, as well as its strategic focus on enhancing its operational capabilities and market position.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.